SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
龙抬头
Lv4
700 积分
2023-12-04 加入
最近求助
最近应助
互助留言
The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition
2天前
已完结
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors
3天前
已完结
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia
3天前
已完结
Philadelphia-chromosome positive acute lymphoblastic leukemia: ten frequently asked questions
6天前
已完结
Tackling Osimertinib Resistance in EGFR-Mutant Non–Small Cell Lung Cancer
13天前
已完结
Acquired resistance mechanisms to osimertinib: The constant battle
13天前
已完结
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
14天前
已完结
Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors
14天前
已完结
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: a scoping review
14天前
已完结
Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019–2024)
14天前
已完结
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
8个月前
已采纳
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
8个月前
已撤回
从其它渠道获得【积分已退回】
3个月前
需要补充文件,不需要正文
3个月前
感谢
6个月前
感谢
6个月前
感谢
6个月前
感谢
7个月前
预印本,是否有正式版本?
8个月前
感谢
8个月前
感谢
8个月前
感谢
8个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论